Genmab

2,062.00 DKK

+1.93 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Investor consensus

+1.93 %

+10.59 %

+18.17 %

+43.34 %

+38.16 %

+34.64 %

-37.08 %

-12.74 %

+5,946.92 %

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Market cap

132.46B DKK

Turnover

193.21M DKK

Revenue

21.53B

EBIT %

31.14 %

P/E

16.87

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5/2

2026

Annual report '25

19/3

2026

General meeting '26

7/5

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Press releaseyesterday

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Regulatory press release12/1/2025, 9:24 PM

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Press release11/24/2025, 12:00 PM

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/20/2025, 8:02 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Regulatory press release11/19/2025, 5:55 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Press release11/18/2025, 9:01 PM

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Regulatory press release11/18/2025, 7:58 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Regulatory press release11/18/2025, 4:30 PM

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Press release11/10/2025, 3:51 PM

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Press release11/10/2025, 12:12 PM

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Regulatory press release11/6/2025, 4:02 PM

Genmab Announces Financial Results for the Nine Months of 2025

Press release11/5/2025, 5:58 PM

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

Press release11/3/2025, 2:05 PM

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Press release10/21/2025, 12:12 PM

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Press release10/18/2025, 10:00 AM

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Regulatory press release10/14/2025, 10:23 AM

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Regulatory press release9/29/2025, 5:08 AM

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Regulatory press release9/25/2025, 11:13 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Regulatory press release9/23/2025, 1:18 PM

Major Shareholder Announcement

Regulatory press release9/9/2025, 6:57 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.